Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Gina Weaver
CONTACT
Lead
Keros Therapeutics, Inc.
This is a Phase 2, multicenter, open-label study of KER-065. The study will consist of 3 periods: * Screening Period (up to 6 weeks) * Treatment Period (48 weeks) * Safety Follow-up Period (4 weeks) Participants will be enrolled in parallel into 1 of 3 treatment cohorts: * Cohort A1 (Late Ambulatory) * Cohort A2 (Late Ambulatory) * Cohort N1 (Early Nonambulatory)
Age
9–any
Sex
MALE
Healthy volunteers
Not accepted